Intranasal delivery of erythropoietin plus insulin-like growth factor-I for acute neuroprotection in stroke: Laboratory investigation

Journal of Neurosurgery

Volumn 111, Issue 1, 2009, Pages 164-170

  Fletcher, Lauren ^a   Kohli, Sanjivan ^b   Sprague, Shane M ^a   Scranton, Robert A ^a   Lipton, Stuart A ^c   Parra, Augusto ^a   Jimenez, David F ^a   Digicaylioglu, Murat ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c BURNHAM INSTITUTE   (United States)

Author keywords

Cytokine; Drug delivery; Erythropoietin; Intranasal delivery; Ischemia; Mouse; Neuroprotective agent

Indexed keywords

IODINE 125; RECOMBINANT ERYTHROPOIETIN; SOMATOMEDIN C;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN FUNCTION; BRAIN RADIOGRAPHY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG PENETRATION; DRUG POTENTIATION; LIQUID SCINTILLATION COUNTING; MALE; MOUSE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; STROKE;

ACUTE DISEASE; ADMINISTRATION, INTRANASAL; ANIMALS; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; DRUG THERAPY, COMBINATION; ERYTHROPOIETIN; INFARCTION, MIDDLE CEREBRAL ARTERY; INSULIN-LIKE GROWTH FACTOR I; IODINE RADIOISOTOPES; MALE; MICE; MICE, INBRED C57BL; NEUROPROTECTIVE AGENTS;

EID: 67650848390     PISSN: 00223085     EISSN: 19330693     Source Type: Journal    
DOI: 10.3171/2009.2.JNS081199     Document Type: Article

References (29)

1. Adams H, Adams R, Del Zoppo G, Goldstein LB: Guidelines for the early management of patients with ischemic stroke: 2005 guidelines update a scientific statement from the Stroke Council of the American Heart Association/American Stroke Association. Stroke 36:916-923, 2005
2. Benedict C, Hallschmid M, Schultes B, Born J, Kern W: Intranasal insulin to improve memory function in humans. Neuroendocrinology 86:136-142, 2007 (Pubitemid 47494214)
3. Bernaudin M, Bellail A, Marti HH, Yvon A, Vivien D, Duchatelle I, et al: Neurons and astrocytes express EPO mRNA: oxygen-sensing mechanisms that involve the redox-state of the brain. Glia 30:271-278, 2000 (Pubitemid 30259666)
4. Bernaudin M, Marti HH, Roussel S, Divoux D, Nouvelot A, MacKenzie ET, et al: A potential role for erythropoietin in focal permanent cerebral ischemia in mice. J Cereb Blood Flow Metab 19:643-651, 1999 (Pubitemid 30161216)
5. Brines ML, Ghezzi P, Keenan S, Agnello D, de Lanerolle NC, Cerami C, et al: Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci U S A 97:10526-10531, 2000 (Pubitemid 30707300)
6. Capsoni S, Giannotta S, Cattaneo A: Nerve growth factor and galantamine ameliorate early signs of neurodegeneration in anti-nerve growth factor mice. Proc Natl Acad Sci U S A 99: 12432-12437, 2002
7. DeVries AC, Nelson RJ, Traystman RJ, Hurn PD: Cognitive and behavioral assessment in experimental stroke research: will it prove useful? Neurosci Biobehav Rev 25:325-342, 2001
8. Digicaylioglu M, Bichet S, Marti HH, Wenger RH, Rivas LA, Bauer C, et al: Localization of specific erythropoietin binding sites in defined areas of the mouse brain. Proc Natl Acad Sci U S A 92:3717-3720, 1995
9. Digicaylioglu M, Garden G, Timberlake S, Fletcher L, Lipton SA: Acute neuroprotective synergy of erythropoietin and insulin-like growth factor I. Proc Natl Acad Sci U S A 101: 9855-9860, 2004 (Pubitemid 38869326)
10. Gozes I, Giladi E, Pinhasov A, Bardea A, Brenneman DE: Activity-dependent neurotrophic factor: intranasal administration of femtomolar-acting peptides improve performance in a water maze. J Pharmacol Exp Ther 293:1091-1098, 2000 (Pubitemid 30417880)
11. Illum L: Is nose-to-brain transport of drugs in man a reality? J Pharm Pharmacol 56:3-17, 2004
12. Jin K, Xie L, Childs J, Sun Y, Mao XO, Logvinova A, et al: Cerebral neurogenesis is induced by intranasal administration of growth factors. Ann Neurol 53:405-409, 2003 (Pubitemid 36258647)
13. Jones JI, Doerr ME, Clemmons DR: Cell migration: interactions among integrins, IGFs and IGFBPs. Prog Growth Factor Res 6:319-327, 1995
14. Juul SE, McPherson RJ, Farrell FX, Jolliffe L, Ness DJ, Gleason CA: Erytropoietin concentrations in cerebrospinal fluid of nonhuman primates and fetal sheep following high-dose recombinant erythropoietin. Biol Neonate 85:138-144, 2004 (Pubitemid 38437682)
15. Kermer P, Digicaylioglu MH, Kaul M, Zapata JM, Krajewska M, Stenner-Liewen F, et al: BAG1 over-expression in brain protects against stroke. Brain Pathol 13:495-506, 2003 (Pubitemid 37420694)
16. Liu XF, Fawcett JR, Thorne RG, DeFor TA, Frey WH II: Intranasal administration of insulin-like growth factor-I bypasses the blood-brain barrier and protects against focal cerebral ischemic damage. J Neurol Sci 187:91-97, 2001
17. Liu XF, Fawcett JR, Thorne RG, Frey WH II: Non-invasive intranasal insulin-like growth factor-I reduces infarct volume and improves neurologic function in rats following middle cerebral artery occlusion. Neurosci Lett 308:91-94, 2001
18. Marti HH, Wenger RH, Rivas LA, Straumann U, Digicaylioglu M, Henn V, et al: Erythropoietin gene expression in human, monkey and murine brain. Eur J Neurosci 8:666-676, 1996 (Pubitemid 26114611)
19. Noguchi CT, Asavaritikrai P, Teng R, Jia Y: Role of erythropoietin in the brain. Crit Rev Oncol Hematol 64:159-171, 2007
20. Rechler MM: Insulin-like growth factor binding proteins. Vitam Horm 47:1-114, 1993
21. Reger MA, Watson GS, Green PS, Wilkinson CW, Baker LD, Cholerton B, et al: Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology 70:440-448, 2008
22. Reinhardt RR, Bondy CA: Insulin-like growth factors cross the blood-brain barrier. Endocrinology 135:1753-1761, 1994 (Pubitemid 24363863)
23. Ruscher K, Freyer D, Karsch M, Isaev N, Megow D, Sawitzki B, et al: Erythropoietin is a paracrine mediator of ischemic tolerance in the brain: evidence from an in vitro model. J Neu rosci 22:10291-10301, 2002 (Pubitemid 35416867)
24. Savaskan E, Ehrhardt R, Schulz A, Walter M, Schachinger H: Post-learning intranasal oxytocin modulates human memory for facial identity. Psychoneuroendocrinology, 2008
25. Thorne RG, Pronk GJ, Padmanabhan V, Frey WH II: Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience 127:481-496, 2004 (Pubitemid 38950662)
26. Wang Y, Zhang ZG, Rhodes K, Renzi M, Zhang RL, Kapke A, et al: Post-ischemic treatment with erythropoietin or carbamylated erythropoietin reduces infarction and improves neurological outcome in a rat model of focal cerebral ischemia. Br J Pharmacol 151:1377-1384, 2007 (Pubitemid 47255890)
27. Ying W, Wei G, Wang D, Wang Q, Tang X, Shi J, et al: Intranasal administration with NAD+ profoundly decreases brain injury in a rat model of transient focal ischemia. Front Biosci 12:2728-2734, 2007
28. Yu YP, Xu QQ, Zhang Q, Zhang WP, Zhang LH, Wei EQ: Intranasal recombinant human erythropoietin protects rats against focal cerebral ischemia. Neurosci Lett 387:5-10, 2005 (Pubitemid 41138199)
29. Zhao HM, Liu XF, Mao XW, Chen CF: Intranasal delivery of nerve growth factor to protect the central nervous system against acute cerebral infarction. Chin Med Sci J 19:257-261, 2004